|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:644-650
© 2006 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
a Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
b Department of Cardiovascular Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan
c Department of Neurology, Okayama University Graduate School of Medicine, Okayama, Japan
Received for publication December 26, 2004; revisions received April 20, 2005; accepted for publication June 20, 2005. * Address for reprints: Yoshiki Sawa, MD, PhD, Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. (Email: sawa{at}surg1.med.osaka-u.ac.jp).
OBJECTIVE: The mechanism of spinal cord injury is believed to be related to the vulnerability of spinal motor neuron cells to ischemia. The aim of this study was to investigate whether ONO-5046, a specific inhibitor of neutrophil elastase that can attenuate tissue or organ injury in various pathologic conditions, could protect against ischemic spinal cord damage.
METHODS: After induction of spinal ischemia, ONO-5046 or vehicle was injected intravenously. Cell damage was analyzed by counting the number of motor neurons. To investigate the mechanism by which ONO-5046 prevents ischemic spinal cord damage, we observed the immunoreactivity of CPP32 (caspase3), brain-derived neurotrophic factor, and phosphorylated extracellular signalregulated kinase.
RESULTS: ONO-5046 eased the functional deficits and increased the number of motor neurons after ischemia. The induction of caspase3 was significantly reduced by ONO-5046 treatment. Furthermore, the expressions of brain-derived neurotrophic factor and phosphorylated extracellular signalregulated kinase were prolonged.
CONCLUSION: ONO-5046 may protect motor neurons from ischemic injury by reducing caspase3 and prolonging the expressions of brain-derived neurotrophic factor and phosphorylated extracellular signalregulated kinase. ONO-5046 may be a strong candidate for use as a therapeutic agent in the treatment of ischemic spinal cord injury.
This article has been cited by other articles:
![]() |
S. Iwamoto, A. Higashi, T. Ueno, M. Goto, Y. Iguro, and R. Sakata Protective effect of sivelestat sodium hydrate (ONO-5046) on ischemic spinal cord injury Interact CardioVasc Thorac Surg, June 1, 2009; 8(6): 606 - 609. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |